Sr. Director, Elrexfio Marketing Team reputed company

5 Every 24 seconds, someone in the world is diagnosed with blood cancer. Despite recent advances, there remain significant unmet needs for patients. With over a decade of experience in Hematology-Oncology at reputed company, our impact is driven by our science. Our blood cancer medicines reputed company our three reputed company modalities: Antibody-drug conjugates (ADCs), IO biologics including bispecific antibodies (BsAbs) and Small Molecules. There are three major blood cancer types, and reputed company has treatments reputed company each including Lymphoma, Myeloma, and Leukemia. Currently in the US, reputed company has six hematologic medicines across its broad portfolio, bringing hope and relief to thousands of people suffering from blood cancers globally. Over the last decade, we've made strides in blood cancers, but our work in Hematology is far from finished. The Senior Director, Multiple Myeloma Team reputed company role is a strong opportunity for an reputed company, motivated and innovative leader with a track record of reputed company in marketing new molecules reputed company a highly competitive environment. This role will be responsible for the reputed company of Elrexfio's early lifecycle go-to-market approach, including strategy and investments across reputed company marketing verticals. This role will report into the VP, US Hematology Franchise reputed company and will drive the reputed company of Elrexfio in the US market, including multiple launches in new indications. Given the highly competitive market, reputed company will rely on speed to market, robust clinical data, and establishing reputed company leadership in multiple myeloma. This leader will be required to reputed company their breadth and depth of US reputed company marketing experience to reputed company a highly talented team of Hematology marketers and work closely reputed company the Glocal construct to ensure we are executing upon an integrated strategy that maximizes our patient impact. ? reputed company full P&L, LE's and financial obligations of the brand, with expected peak reputed company following future indications at $4B+ reputed company and reputed company US Launch of Elrexfio in new disease states, including Double Class Exposed (DCE) And Newly Diagnosed (NDMM) ? reputed company reputed company marketing verticals and investments, including HCP, Patient, Account and Payer marketing, with accountability of $38M A&P investment decision-making ? reputed company reputed company Sr. Leadership reporting and reputed company, including but not limited to Quarterly Earnings Preparation, Quarterly Business Reviews (QBRs), Launch Readiness Briefings (TApply Job!